

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Shun Lu (“**Dr. Lu**”) has been appointed as an independent non-executive Director and a member of the strategy committee of the Board (the “**Strategy Committee**”), with effect from February 9, 2024.

The biographical details of Dr. Lu are set out below:

Dr. Shun Lu

Dr. Shun Lu (陸舜), aged 59, has over 30 years of experience in the medical and pharmaceutical industry. Dr. Lu is currently a professor and the chief of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, and has been in these positions since 2006. Prior to that, Dr. Lu has been an associate professor and the vice chief of the Department of Chest, Shanghai Chest Hospital, Jiao Tong University from January 2000 to December 2005, an attending doctor at the Department of Chest from January 1995 to December 1999, and a resident doctor at the Department of Chest from July 1988 to December 1994.

Dr. Lu holds a medical doctoral degree (major in clinical medicine) from Shanghai Medical University in the People’s Republic of China (“**PRC**” or “**China**”) in 1988 and a doctor of philosophy degree (major in oncology) from Second Military Medical University in the PRC in 2008.

Dr. Lu holds the following professional memberships and qualifications:

- Former director of Chinese Society of Lung Cancer, China Anti-cancer Association
- Standing director of Chinese Society of Clinical Oncology (“**CSCO**”) and vice president of CSCO Foundation
- Chairman of Advisory Board of DIA China
- Former director of Oncology Society, Shanghai Medical Association
- Board member of Oncology Society, Chinese Medical Association, and chairman of Lung Cancer Expert Committee

- Chairman of Oncology Branch of Shanghai Medical Doctor Association
- Associate editor of Journal of Thoracic Oncology, associate editor of Lung Cancer, and editorial board member of The Oncologist
- Standing director of Shanghai Anti-cancer Association
- Vice chairman of Precision Medicine Branch, China Medicinal Biotech Association

Dr. Lu has presided over several research programs, including national major projects of the Ministry of Science and Technology for chronic disease, and international cooperation projects; national new drug innovation major projects and two sub-projects of 863 Major Programs (863 重大課題子課題 2 項); key programs of National Natural Science Foundation of China, lung cancer special programs and other general programs.

In addition, Dr. Lu has made outstanding contribution to society and the community, and he was awarded a number of national and provincial titles, including National Expert with outstanding contributions in health (國家衛生健康突出貢獻中青年專家), Shanghai Leading Talent (上海市領軍人才), Shanghai Excellent Academic Leader (上海市優秀學術帶頭人), and Chief Specialist of National Key Programs (國家重點專項首席專家). Dr. Lu also received a number of awards, such as First prize of Science and Technology Award of China Anti-cancer Association (中國抗癌協會科技獎一等獎), First prize of Shanghai Medical Science and Technology Award (上海市醫學科技獎一等獎), Second prize of Huaxia Medical Science and Technology Award (華夏醫學科技獎二等獎), First prize of Shanghai Scientific and Technology Progress Award (上海市科技進步一等獎), President's Award of Shanghai Jiao Tong University (上海交通大學校長獎), 2018 "Kind-hearted Doctor" – Shanghai Outstanding Specialty Physician Nomination Award (2018 年仁心醫者•上海市傑出專科醫師提名獎), and 2021 WuXi AppTec Research Award in Biochemistry (2021 年「藥明康德生命化學研究獎」).

Dr. Lu has entered into a letter of appointment with the Company for a term of one (1) year commencing on February 9, 2024 and until terminated by either party by giving at least 3 months' notice. Dr. Lu is subject to retirement by rotation and re-election at the forthcoming annual general meeting in accordance with the memorandum and articles of association of the Company and the Corporate Governance Code as set out in Appendix C1 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Dr. Lu shall not be entitled to receive any remuneration under his letter of appointment.

Save as disclosed above, as at the date of this announcement, (i) Dr. Lu does not hold any other position in the Company or its subsidiaries; (ii) Dr. Lu does not hold any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three (3) years; (iii) Dr. Lu does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance; (iv) Dr. Lu does not have any relationship with any Directors, senior management, substantial shareholders (as defined under the Listing Rules) or controlling shareholders (as defined under the Listing Rules) of the Company; and (v) Dr. Lu does not possess any other professional qualifications.

Dr. Lu has confirmed that (i) he meets the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment. Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Dr. Lu that need to be brought to the attention of the Shareholders, nor is there any other information which is required to be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend a warm welcome to Dr. Lu on his appointment.

By order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, February 9, 2024

As at the date of this announcement and following the above appointment of Director, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula and Dr. Shun Lu as Independent Non-executive Directors.